1. Scrip
  2. >>Conferences
  3. >>ASCO

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

Could Merck/Kelun Come Out On Top?

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

• Source: Shutterstock

Emerging data on the field of TROP2-targeted antibody-drug conjugates – namely Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy), Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s (datopotamab deruxtecan (Dato-DXd) and Merck & Co., Inc./Sichuan Kelun Pharmaceutical Co Ltd.’s sacituzumab tirumotecan (Sac-TMT) – suggest that developers need to aim for subgroups of non-small cell lung cancer rather than all-comers, and that the drugs are more likely to work in earlier-line disease combined with checkpoint inhibitors.

Key Takeaways

  • ASCO featured Phase II and Phase III data from three competing TROP2-directed ADCs in non-small cell lung cancer, giving a glimpse of the future competitive field

Detailed data from Gilead’s failed Phase III EVOKE-01 trial of Trodelvy, the investigator-sponsored Phase II ICARUS-Lung01 trial of Dato-DXd and Kelun’s Phase II OptiTROP-Lung01 trial of Sac-TMT combined with its PD-L1 inhibitor KL-A167 were presented

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.